Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016

• Published in: Euro surveillance : bulletin européen sur les maladies transmissibles 2019-02, Vol.24 (7)
• Main Authors: Martínez-Gómez, Xavier, Curran, Adrian, Campins, Magda, Alemany, Laia, Rodrigo-Pendás, José Ángel, Borruel, Natalia, Castellsagué, Xavier, Díaz-de-Heredia, Cristina, Moraga-Llop, Fernando A, Del Pino, Marta, Torné, Aureli
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Child; Consensus; Effectiveness; Evidence-based medicine; Female; Homosexuality, Male; Human papillomavirus; Humans; Immunization; Male; Papillomaviridae; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - administration & dosage; Papillomavirus Vaccines - therapeutic use; Practice Guidelines as Topic; Precancerous Conditions - prevention & control; Precancerous Conditions - virology; Review; Risk; Spain; Systematic review; Uterine Cervical Neoplasms - prevention & control; Uterine Cervical Neoplasms - virology; Vaccination; Young Adult
• ISSN: 1560-7917; 1025-496X; 1560-7917
• DOI: 10.2807/1560-7917.ES.2019.24.7.1700857

Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9-26 years; men who have sex with men aged 9-26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9-26 years; and patients diagnosed with recurrent respiratory papillomatosis. Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.